MK 869. L 754030, MK 0869.
D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D000077608:Aprepitant; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D009025:Morpholines / Q000009:adverse effects / Q000627:therapeutic use*; D064729:Neurokinin-1 Receptor Antagonists; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D013373:Substance P / Q000037:antagonists & inhibitors; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D000970:Antineoplastic Agents; D009025:Morpholines; D064729:Neurokinin-1 Receptor Antagonists; D010919:Placebos; D000077608:Aprepitant; D013373:Substance P